ICD-10-CM 2027 diagnosis code
D3A.091Benign carcinoid tumor of the thymus
D3A.091 is a valid, billable ICD-10-CM code for benign carcinoid tumor of the thymus. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About D3A.091
D3A.091 is the ICD-10-CM diagnosis code for benign carcinoid tumor of the thymus. It belongs to category D3A (benign neuroendocrine tumors), block D3A (benign neuroendocrine tumors) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within D3A.09 (benign carcinoid tumors of other sites), D3A.091 is specifically for benign carcinoid tumor of the thymus. Related codes cover tumor of the bronchus and lung (D3A.090), tumor of the stomach (D3A.092), tumor of the kidney (D3A.093), tumor of the foregut, unspecified (D3A.094), tumor of the midgut, unspecified (D3A.095), tumor of the hindgut, unspecified (D3A.096) and tumors of other sites (D3A.098).
Use an additional code to identify any associated endocrine syndrome, such as: carcinoid syndrome (E34.00).
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 209.62 (benign carcinoid tumor of the thymus).
Notes that apply from higher levels
Instructions written at a parent level also apply to D3A.091.
Broader instructions also apply from Chapter 2: Neoplasms.
Alphabetic index entries
1 entriesTerms in the official ICD-10-CM index that lead to D3A.091.
Codes whose notes reference D3A.091
- D15.0Excludes1
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 16 · Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders
ICD-9-CM equivalent
Converter →- 209.62Benign carcinoid tumor of the thymusexact
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about D3A.091
Is D3A.091 billable?
- Yes. D3A.091 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D3A.091 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D3A.091 as a principal diagnosis.
Is D3A.091 a CC or MCC?
- No. D3A.091 is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does D3A.091 group to?
- D3A.091 is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for D3A.091?
- The CMS General Equivalence Mappings map D3A.091 to ICD-9-CM 209.62.